Bernard emphasized strong performances in the QIAstat Diagnostics and QuantiFERON portfolios, with QIAstat achieving 25% CER growth in Q4 and over 660 new system placements in 2024. QuantiFERON grew ...

Reports Q4 revenue $521M, consensus $518.54M. The company said, “Our solid sales growth in the second half of 2024 mirrors our plans for ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced financial results for the fourth quarter and ...

The company made significant strides in the QIAcuity digital PCR system, including the addition of 100 new validated assays in areas such as cancer research, inherited genetic disorders and ...

QIAGEN N.V.’s QGEN long-term business strategy focuses on forming partnerships for the development, commercialization, marketing and distribution of existing and future products. The company sees ...